Ashurst
We only have limited information for this firm. Consider the following firms which have provided more information:
Ashurst advises a varied mix of issuers, underwriters and sponsors across the life-cycle of ECM matters, including on IPOs, general compliance matters, spin-off listings, secondary offerings, block trades and buy backs. Although the firm is industry agnostic, it has been particularly active in recent years in relation to ECM transactions in the pharmaceutical, biotech and digital economy sectors, all of which have experienced an uptick of issuances as a result of regulatory changes. ‘The very responsive and hardworking’ Frank Bi has particularly strong traction with Chinese issuers, including SOEs, which are appreciative not only of his legal skills but also his language capabilities. The team is also able to link up with international colleagues spread throughout the firm’s vast network on cross-border issues, while Melody He and the ’outstanding’ Li Jiang leverage their US qualifications to good effect on behalf of Asian entities listing in the US. Bi co-heads the firm’s overarching Asia corporate offering with Joshua Cole.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The team has extensive experience in Hong Kong ECM projects. They are very familiar with the development of relevant industries and regulatory trends, and can customise targeted legal solutions based on comprehensive regulatory requirements and clients' business needs.'
'The very responsive and hardworking Frank Bi provides effective solutions which are tailored to the client's specific needs.'
Abbreviated data is displayed for this firm.
Key clients
- CLSA
- UBS Securities Hong Kong Limited
Abbreviated data is displayed for this firm.
Work highlights
- Advised UBS Securities Hong Kong Limited, Essence Corporate Finance (Hong Kong) Limited as joint sponsors and underwriters on the HK$212m Hong Kong IPO of Shandong Boan Biotechnology Co., Ltd. and its spinoff listing on the Hong Kong Stock Exchange from Luye Pharma Group Ltd.
- Advised Zhongtai International Capital Limited as sole sponsor and the underwriters on the HK$314m Hong Kong IPO and Regulation S offering of Many Idea Cloud Holdings Limited, an integrated marketing and SaaS services company in China.
Abbreviated data is displayed for this firm.